Get the Stockscreener App
8.44
26.93%
-3.11
Exicure Inc stock is traded at $8.44, with a volume of 62,355.
It is down -26.93% in the last 24 hours and down -35.03% over the past month.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.
See More
Previous Close:
$11.55
Open:
$11.8
24h Volume:
62,355
Relative Volume:
1.17
Market Cap:
$74.11M
Revenue:
$28.83M
Net Income/Loss:
$-13.34M
P/E Ratio:
-5.5526
EPS:
-1.52
Net Cash Flow:
$-7.49M
1W Performance:
-25.31%
1M Performance:
-35.03%
6M Performance:
+190.03%
1Y Performance:
+182.51%
1-Day Range:
$8.28
$11.83
1-Week Range:
$8.28
$12.29
52-Week Range:
$1.44
$36.00
Exicure Inc Stock (XCUR) Company Profile
Name
Exicure Inc
Sector
Industry
Phone
847-673-1700
Address
2430 N. HALSTED ST., CHICAGO, IL
Compare XCUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
0.2623 | 398.00M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.21 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1717 | 347.36M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
JUNE
Dhandho Junoon Etf
|
11.11 | 204.17M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.91 | 131.34M | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-18-20 | Initiated | BMO Capital Markets | Outperform |
| Nov-20-19 | Initiated | Guggenheim | Buy |
Exicure Inc Stock (XCUR) Latest News
Exicure, Inc. (NASDAQ:XCUR) Sees Large Drop in Short Interest - Defense World
Exicure Close to Finishing Patient Recruitment in Phase 2 Study of GPC-100 in Multiple Myeloma - MarketScreener
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma - BioSpace
Breakthrough: New Multiple Myeloma Treatment Achieves Perfect Success Rate in Trial - Stock Titan
Exicure appoints new independent accounting firm By Investing.com - Investing.com South Africa
Exicure appoints new independent accounting firm - Investing.com
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) - BioSpace
New Clinical Trial: Exicure's GPC-100 Shows Promise in Fighting Acute Myeloid Leukemia - Stock Titan
How to Take Advantage of moves in (XCUR) - news.stocktradersdaily.com
Eli Lilly and Company (NYSE:LLY) and Exicure (NASDAQ:XCUR) Head to Head Analysis - Defense World
Short Interest in Exicure, Inc. (NASDAQ:XCUR) Grows By 58.5% - Defense World
Wednesday’s Insider Moves: Top Buys and Sells in US Stocks - Investing.com India
Wednesday’s Insider Moves: Top Buys and Sells in US Stocks By Investing.com - Investing.com UK
Trading (XCUR) With Integrated Risk Controls - news.stocktradersdaily.com
Major Investment Alert: HiTron Systems Inc. Boosts Stake in Exicure! - TipRanks
HiTron Systems acquires $8.7 million in Exicure stock By Investing.com - Investing.com Canada
HiTron Systems acquires $8.7 million in Exicure stock - Investing.com
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Exicure, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm - Business Wire
Exicure Inc Reports $9.7 Million Net Loss for Fiscal Year 2024 A - GuruFocus
Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference - Business Wire
Short Interest in Exicure, Inc. (NASDAQ:XCUR) Increases By 24.2% - Defense World
Exicure, Inc. Reports Full Year 2024 Financial Results - BioSpace
EXICURE, INC. SEC 10-K Report - TradingView
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Exicure, Inc. Investors to Secure Counsel Before Important February 11 Deadline in Securities Class Action – XCUR - Business Wire
Pre-Market Momentum: Exicure (XCUR) Shares Rise After Key Approval - Stocks Telegraph
When (XCUR) Moves Investors should Listen - Stock Traders Daily
Exicure Gets Patent in Australia for Potential Cancer Treatment Combination -March 14, 2025 at 04:32 am EDT - Marketscreener.com
Exicure secures Australian patent for cancer treatment - Investing.com Australia
Exicure, Inc. Announces Issuance Of New Patent In Australia -March 13, 2025 at 05:39 pm EDT - Marketscreener.com
Exicure announces issuance of new patent in Australia - TipRanks
Exicure secures Australian patent for cancer treatment By Investing.com - Investing.com South Africa
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia - Business Wire
Exicure's New Cancer Patent Breakthrough Powers Multiple Myeloma Clinical Trial - Stock Titan
Pre-market Movers: HCTI, HEPA, ZYXI, SYRS ... - RTTNews
Exicure announces board member departures, transitions By Investing.com - Investing.com Australia
(XCUR) Technical Pivots with Risk Controls - Stock Traders Daily
Exicure announces board member departures, transitions - Investing.com
Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 16.2% in February - Defense World
Where are the Opportunities in (XCUR) - Stock Traders Daily
Exicure (NASDAQ:XCUR) Stock Price Down 1.6% – Time to Sell? - Defense World
Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes - MSN
How To Trade (XCUR) - Stock Traders Daily
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease - Citeline News & Insights
How the (XCUR) price action is used to our Advantage - Stock Traders Daily
Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 17.3% in January - Defense World
Hitron Systems Inc. announced that it expects to receive KRW 30 billion in funding -September 05, 2024 - Marketscreener.com
Exicure Inc (XCUR) requires closer examination - US Post News
Exicure signs purchase agreement with GPCR Therapeutics - MSN
Exicure, back from brink and under new management, buys GPCR's US unit and clinical-stage drug - Fierce Biotech
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. - BioSpace
Exicure Inc Stock (XCUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):